Exploring Seer, Inc. (SEER) Investor Profile: Who’s Buying and Why?

You're looking at Seer, Inc. (SEER) and wondering who is actually buying this proteomics pioneer, especially when the Q3 2025 earnings show a mixed bag. Honestly, the institutional money is the story here, holding around 61.62% of the shares, totaling over 28.6 million shares, with giants like BlackRock, Inc. and Vanguard Group Inc. still in the mix, which defintely signals long-term conviction in the Proteograph platform's (a system for large-scale protein analysis) potential. But you have to ask: why are they holding when the company just reported a Q3 revenue of only $4.1 million, even while maintaining a full-year guidance of $17 million to $18 million, and still burning cash with a net loss of $18.2 million for the quarter? The simple answer is the balance sheet: they ended Q3 with a hefty war chest of approximately $251.2 million in cash and investments, giving them a long runway to execute in a tough capital expenditure environment. So, are the big funds betting on a proteomics breakthrough finally translating to sales, or are they just looking at the deep-value cash position? Let's break down the major players, their recent moves, and what their buying-or selling-tells you about Seer's true near-term risk and opportunity.

Who Invests in Seer, Inc. (SEER) and Why?

You're looking at Seer, Inc. (SEER) because you know the proteomics space is the next frontier in life sciences, but the stock's volatility is a real head-scratcher. The core takeaway is that the investor base is heavily skewed toward long-term, high-conviction holders-the insiders and venture capital (VC) funds that backed the company's proprietary technology early on.

The ownership structure shows a clear separation between those who built the company and the public market funds. This composition means the stock price is less sensitive to day-to-day retail trading noise, but major moves by the large insider block can still cause significant price swings.

Key Investor Types: The Ownership Breakdown

The investor profile for Seer, Inc. is unusual because the majority of shares are held by insiders and the original venture capital backers. This is typical for a growth-stage biotech company commercializing a transformative product like the Proteograph Product Suite. As of the 2025 fiscal year, the ownership breakdown is heavily concentrated:

• Institutional Investors: Approximately 13.01%
• Insider Investors (VC/Founders/Management): Approximately 55.80%
• Retail Investors: Approximately 31.19%

Here's the quick math: Over half the company is held by people and funds who were there at the beginning. That's a huge block of stock that isn't actively traded.

The institutional slice includes the passive giants like The Vanguard Group, Inc. and BlackRock, Inc., who hold shares primarily through index-tracking funds. But it also includes active hedge funds like Renaissance Technologies Llc and Tang Capital Management Llc, whose positions are typically more dynamic.

Investment Motivations: Betting on Proteomics Technology

Investors are buying Seer, Inc. for one core reason: the belief that its Proteograph technology will become the standard for deep, unbiased proteomics (the large-scale study of proteins). This isn't a dividend play-the company is still in the growth phase, reporting a net loss of $18.2 million in the third quarter of 2025.

The motivation is pure growth and market leadership. The company's success in 2025 is tied directly to the adoption of its platform. They shipped nearly three times as many instruments in the first nine months of 2025 as they did in all of 2024, which is a powerful sign of growing customer validation. This is what the insiders are anchored to.

Mission Statement, Vision, & Core Values of Seer, Inc. (SEER).

The financial path to profitability is clear, even if it's distant. Management is guiding for full-year 2025 revenue in the range of $17 million to $18 million and has a long-term goal of achieving gross margins of 70-75%, which is the kind of number that gets growth investors defintely excited. The company's strong liquidity, with approximately $251.2 million in cash, cash equivalents, and investments as of September 30, 2025, also buys them a long runway to execute this vision.

Investment Strategies: Long-Term Conviction vs. Active Trading

The strategies employed by the major holders of Seer, Inc. stock reflect a classic split between passive, long-term conviction and active, catalyst-driven trading.

The largest holders are the original backers, such as Softbank Group Corp. and aMoon Ventures Y.SH. Ltd. These are long-term, high-conviction growth investors. Their strategy is simple: hold for years, waiting for the technology to mature and dominate the market. They are looking for a 10x return, not a 10% gain.

On the other side, you have the institutional funds.

What this estimate hides is the true nature of the 'Insider' category; many of those shares are held by VC funds like aMoon, who are not employees but are deep-pocketed, patient partners. The fact that the stock has a high beta (volatility) reflects the high stakes: it's a bet on a revolutionary technology, not on stable earnings.

Your action here is to decide which camp you belong in: are you a long-term technology believer, or are you looking to trade the volatility around product milestones?

Institutional Ownership and Major Shareholders of Seer, Inc. (SEER)

You're looking at Seer, Inc. (SEER) and trying to figure out who the big money is betting on, and why. That's smart. Institutional ownership-the holdings of mutual funds, pension funds, and major asset managers like BlackRock, Inc.-is a critical signal, especially for a growth-stage company in the proteomics space. It tells you who has done the deepest due diligence.

The direct takeaway is that institutional investors hold a significant majority, but their recent activity shows a clear divergence of opinion. As of the most recent filings, institutions own approximately 61.62% of Seer, Inc.'s outstanding shares. That's a high conviction level from the professional money management world, but it's still a volatile stock. The share price as of November 10, 2025, was $2.09 per share.

Top Institutional Investors and Their Stakes

The institutional roster for Seer, Inc. is a mix of passive index funds and more active, specialized investors. These are the entities holding the most sway over the stock's long-term stability and liquidity. In total, 114 institutional owners have filed with the SEC, holding a combined total of 28,602,649 shares.

The presence of major index fund managers means a portion of the institutional ownership is passive-they buy the stock because it's in an index they track. But the presence of specialized funds suggests a deeper, more active belief in the Proteograph platform's technology. You'll see names like Softbank Group Corp and Siren, L.L.C. alongside the behemoths.

• Softbank Group Corp: Major venture capital backing.
• Vanguard Group Inc: Significant passive index exposure.
• BlackRock, Inc.: Global asset management giant.
• Acadian Asset Management Llc: Quant-focused investment manager.
• Renaissance Technologies Llc: Highly quantitative hedge fund.

The Mixed Signal of Recent Ownership Changes

This is where the story gets interesting, and frankly, a little complicated. Over the last quarter, we've seen significant movement, which is typical for a smaller-cap biotech or life sciences tool company navigating a tough market. The institutional trading volume shows a net selling trend, but there's a key nuance to that number.

In the last quarter, institutions bought 21.1 million shares but sold a much larger volume of 47.7 million shares. Here's the quick math: that's a net outflow of 26.6 million shares from institutional portfolios. This net selling is a clear headwind, indicating that for every dollar of new money coming in from institutions, more than two dollars are heading out.

Still, the company itself is stepping in. Seer, Inc. repurchased approximately 1.0 million shares in Q3 2025. That share buyback program reflects management's confidence, and it helps to offset some of the selling pressure, defintely a positive sign for the remaining investors.

Plus, some individual major shareholders have also reduced their stakes significantly in 2025, including a 67.11% reduction by Radoff Bradley Louis and a 29.01% reduction by Farokhzad Omid, according to 13G/A filings. This is a critical data point for you to consider, as large insider or early-investor selling often signals a change in conviction or a need for liquidity.

Impact on Stock Price and Corporate Strategy

The high institutional ownership percentage-over 60%-means these large investors are the primary drivers of the stock price and its volatility. When institutions sell, the price moves down quickly because their trade sizes are massive. When they buy, it provides a floor. It's that simple.

More importantly, institutional investors dictate strategy. A large, passive holder like Vanguard Group Inc is generally hands-off, filing a 13G (passive investment). But an active investor, especially one that files a 13D (indicating intent to influence strategy), can push for significant changes, like cost-cutting, a sale of the company, or a shift in the R&D focus.

For Seer, Inc., the institutional capital provides a crucial runway. The company reported a strong cash position of approximately $251 million in cash, cash equivalents, and investments as of Q3 2025. This cash cushion, backed by investor capital, allows management to focus on their strategic initiatives, such as driving larger cohort studies and expanding their user base, rather than constantly worrying about immediate funding. The strategic focus is clear: external validation of the Proteograph platform. You can read more about the company's financial health and runway in our deeper dive: Breaking Down Seer, Inc. (SEER) Financial Health: Key Insights for Investors.

The company's participation in investor conferences in November 2025, like the UBS Global Healthcare Conference, shows they are actively managing this institutional relationship, trying to convince the market that their full-year 2025 revenue guidance of $17-$18 million is achievable, despite the current market headwinds.

Key Investors and Their Impact on Seer, Inc. (SEER)

You're looking at Seer, Inc. (SEER) and trying to figure out who the big players are and what their recent moves mean for the stock. This is smart. In a specialized sector like proteomics, the institutional backing often signals confidence in the long-term technology, even when near-term financials are still developing. The direct takeaway is that while the institutional base is broad and includes major passive funds, recent activity shows a mix of conviction and caution, with a significant insider selling trend that you defintely need to keep an eye on.

As of late 2025, Seer, Inc. has a substantial institutional footprint, with 114 institutional owners and shareholders holding a total of over 28.6 million shares. This isn't a small-cap stock flying under the radar; it's got serious money behind it. The presence of these large funds provides a baseline of stability, but their trading actions are where the real story is.

The Anchor Investors: Who Holds the Bulk?

The investor profile for Seer, Inc. is anchored by some of the biggest names in asset management. These are the funds that hold the largest stakes, often through passive index funds or large-scale, long-term growth strategies. Their sheer size means their decisions can move the stock, but their influence is typically passive unless they cross the 5% ownership threshold and file a Schedule 13D, which signals an intent to actively pursue a change in strategy.

The largest shareholders you should know about include:

• Softbank Group Corp: A major venture capital and technology investor, signaling belief in Seer's disruptive technology.
• Vanguard Group Inc: A behemoth of passive investing, holding shares primarily through index funds like the VTSMX - Vanguard Total Stock Market Index Fund Investor Shares.
• BlackRock, Inc.: Another massive asset manager whose holdings are often a reflection of index inclusion, but their trading volume is still huge.
• Renaissance Technologies Llc: A quantitative hedge fund known for its high-frequency, data-driven trading strategies.

The fact that a company like BlackRock, Inc. is a top holder means the stock is part of the broader market ecosystem. That's a good sign for liquidity. For a deeper dive into the company's fundamentals, you can check out Breaking Down Seer, Inc. (SEER) Financial Health: Key Insights for Investors.

Recent Moves: A Tale of Two Quarters in 2025

Looking at the Q2 and Q3 2025 filings, we see a clear divergence in institutional sentiment. While 31 institutional investors added shares in the most recent quarter, 32 decreased their positions. This kind of back-and-forth shows the market is still debating Seer, Inc.'s valuation and growth trajectory, especially as the company works toward its full-year revenue guidance of $17 million to $18 million.

Here's the quick math on some notable Q2 2025 activity:

The Citadel Advisors LLC move, a massive 510.2% increase in their position, is a strong vote of confidence from a major hedge fund. But still, the Q1 2025 exit of 900,000 shares by TANG CAPITAL MANAGEMENT LLC, a biotech-focused fund, shows that some specialized investors are taking profits or reducing exposure. This is a push-pull dynamic, not a unified stampede.

Investor Influence and Company Actions

Investor influence isn't just about buying or selling; it's about what the company does in response to market signals. The most significant action in Q3 2025 was Seer, Inc.'s own share repurchase program. The company bought back approximately 1.0 million shares, which reduced the net total shares outstanding by about 14%. That's a strong signal from management that they believe the stock is undervalued, especially with a cash position of approximately $251 million as of September 30, 2025, giving them a long runway.

However, the insider trading tells a different story. In the six months leading up to July 2025, insiders made 5 sales and 0 purchases. For example, CEO Omid Farokhzad sold 41,731 shares for an estimated $87,898. When the people who know the company best are selling, even in small amounts, it's a yellow flag. It doesn't mean the company is failing, but it suggests they see better opportunities elsewhere or are simply diversifying their personal wealth. You need to weigh the company's confidence (share buyback) against the insiders' caution (consistent selling).

Market Impact and Investor Sentiment

You're looking at Seer, Inc. (SEER) and trying to figure out if the big money is still on board, and honestly, the sentiment is a mixed bag-a classic high-growth, pre-profit biotech story. The core investor belief remains anchored to the Proteograph Product Suite's potential, but near-term execution and macro headwinds are causing institutional churn. This is a conviction stock, not a consensus one.

The institutional ownership is still significant, with 61.62% of the stock held by major funds, but recent trading shows caution. In the last reported quarter, institutions sold approximately 47.7 million shares while buying 21.1 million shares, a clear net outflow. That's a massive amount of capital taking risk off the table, but the remaining holders are the ones with the deepest conviction in the proteomics platform.

• Institutional ownership is high, but net selling is a headwind.
• Management is stepping up to defend the price.

The most bullish signal, however, comes directly from management's own actions: Seer, Inc. has repurchased approximately $22 million of its Class A common shares under its $25 million program, effectively reducing the net total shares outstanding by about 14%. This tells me management believes the stock is defintely undervalued, and they are using their balance sheet-which held a strong $251.2 million in cash, cash equivalents, and investments as of September 30, 2025-to back that belief.

Recent Market Reactions and Ownership Shifts

The market's reaction to Seer, Inc.'s operational progress this year has been largely skeptical, which is typical for a growth stock in a tight funding environment. For example, after the Q2 2025 earnings report, where the company actually beat expectations (revenue of $4.1 million versus a $4.05 million forecast), the stock still dipped by 2.83% in after-hours trading to $2.06. This reaction suggests investors are prioritizing the path to profitability over incremental revenue beats.

The insider activity is another point of caution. Over the last six months, company insiders, including CEO Omid Farokhzad and other executives, have executed five sales and zero purchases. While these sales are often pre-scheduled, the optics of the Founder netting US$70k from a sale in May 2025 adds to the negative narrative. When insiders are selling, it makes you wonder what they think of the current valuation.

Here's the quick math on their financial position: Q3 2025 net loss was $18.2 million. With $251.2 million in cash, they have a long runway, but the market is demanding a clear inflection point. The stock's high beta of 1.58 confirms its volatility, meaning it exaggerates the market's movements, making it a riskier bet for passive money.

Analyst Perspectives and Key Investor Validation

The analyst community, while quiet on recent price targets, has given a strong nod to the company's technology. The lack of fresh price targets is a liquidity signal, not necessarily a technology one. However, the biggest validation came when the Proteograph platform was selected as the sole proteomics technology for a major NIH-funded multi-omic study, a project valued at $50 million involving 50,000 samples. This is a massive, third-party endorsement of the platform's capabilities and its potential to reveal biological insights that others do not.

Top institutional holders like Softbank Group Corp, Vanguard Group Inc, and BlackRock, Inc. are the ones who are essentially underwriting this long-term technological bet. For instance, Vanguard Group Inc held 2,221,404 shares as of early November 2025. Their presence, alongside other index funds, suggests a belief in the long-term adoption of deep, unbiased proteomics (protein analysis) in the life sciences market.

The company's full-year 2025 revenue guidance is still in the range of $17 million to $18 million, an expected growth of 24% at the midpoint over 2024, but management has already flagged that macro pressures will likely push them toward the lower end of that range. The opportunity remains tied to the adoption of their new instruments, like the SP200 Automation Instrument, which made up almost two-thirds of instrument shipments through September 30, 2025. For a deeper dive into the company's long-term vision, you should review their Mission Statement, Vision, & Core Values of Seer, Inc. (SEER).

Your next step should be to monitor the Q4 2025 instrument shipment numbers, as this is the clearest sign of customer adoption and future consumable revenue. That's the action that will change the decision.